Business
Karyopharm Reports Strong Third Quarter 2021 Financial Results and Provides Business Highlights
-- Third Quarter 2021 XPOVIO® (selinexor) Net Product Revenues of $26.7 Million, Up 32% Sequential Quarter-Over-Quarter and 25% Year-Over-Year -- --
About this update from Karyopharm Therapeutics Inc.
[{"type":"text","content":"-- Third Quarter 2021 XPOVIO® (selinexor) Net Product Revenues of $26.7 Million, Up 32% Sequential Quarter-Over-Quarter and 25% Year-Over-Year --\n -- Milestone-Driven Q4 with Top-Line Data From Phase 3 SIENDO Study in Endometrial Cancer and Continued Initiation and Expansion of Key Clinical Trials in Multiple Myeloma, Myelodysplastic Syndromes and Myelofibrosis --\n -- Conference Call Scheduled for Today at 8:30 a.m. ET --\n -- Company to Host Virtual Investor Day on December 8, 2021 to Outline Commercial and Pipeline Priorities and Objectives --\n\n\nNEWTON, Mass., Nov. 3, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended September 30, 2021 and provided business highlights.\n\"Driven by acceleration in demand growth for XPOVIO, Karyopharm delivered a strong third quarter, which saw a significant increase in net product revenues versus the second quarter of 2021. XPOVIO continues to move into earlier lines of therapy in multiple myeloma as a new and effective modality that can become the standard of care in second line plus where utilizing new mechanisms is critical to improve patient outcomes,\" said Richard Paulson, President and Chief Executive Officer of Karyopharm. \"With respect to the pipeline, we remain focused on expanding key clinical trials in multiple myeloma, as well as in additional cancer indications such as endometrial cancer, myelodysplastic syndromes and myelofibrosis, as emerging data continue to guide our clinical programs. Looking ahead, we have several key upcoming milestones including reporting top-line data from the Phase 3 SIENDO study in endometrial cancer where recruitment remains on track. Finally, we look forward to hosting an Investor Day in early December to present further details on our commercial and pipeline priorities.\"\nThird Quarter 2021 and Recent Highlights\nXPOVIO Commercial Performance\nAchieved U.S. net product revenue for the third quarter of 2021 of $26.7 million. This represents 32% growth compared to the second quarter of 2021 and 25% growth compared to the third quarter of 2020. Moving into earlier lines of treatment and increasing use of once weekly XPOVIO-based triplet regimen. Growing breadth and depth of adoption and building physi...